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Background and aims: Matrix metalloproteinase (MMP)-8 and myeloperoxidase (MPO) may contribute to
cerebral damage in acute ischemic stroke. We tested the hypothesis that levels of MPO, MMP-8 and the
ratio between MMP-8 and its regulator, tissue inhibitor of metalloproteinase (TIMP-1), are increased in
acute ischemic stroke and its etiologic subgroups and they correlate with stroke severity.
Methods: In a cross-sectional caseecontrol study, serum concentrations of MMP-8, MPO and TIMP-1
were assessed within 24 h after admission in 470 first-ever ischemic stroke patients and 809 age- and
sex-matched controls, randomly selected from the population. Odds ratios (OR) per decade of log
transformed dependent variables were calculated and adjusted for age, sex and vascular risk factors.
Results: Levels of MMP-8 (OR 4.9; 95% CI 3.4e7.2), MMP-8/TIMP-1 ratio (3.0; 2.2e4.1) and MPO (6.6; 4.0
e11.0) were independently associated with ischemic stroke. MMP-8 levels differed between etiologic
stroke subgroups (p¼ 0.019, ANOVA), with higher levels in cardioembolic stroke and stroke due to large
vessel disease, and lower levels in microangiopathic stroke. MMP-8, MMP-8/TIMP-1 ratio and MPO (p <
0.001) concentrations showed positive associations with stroke severity independent of stroke etiology.
Conclusions: Concentrations of serum neutrophil markers are increased after ischemic stroke and
associate with stroke severity and etiology. The value of these biomarkers in diagnostics and prognostics
is worth being evaluated.
© 2018 Elsevier B.V. All rights reserved.1. Introduction
Stroke is one of the major causes of death and disability
worldwide [1]. Demographic changes will lead to increasing
numbers of stroke patients [2]. Optimizing stroke prevention and
acute stroke care is mandatory. Systemic inflammation plays a key
role in both stroke formation and immediate tissue damage post
stroke [3]. Identification of specific proinflammatory biomarkers
might give an opportunity to lower stroke risk and enhance acute
stroke care.
We recently described higher serum concentrations of matrix, St€adtisches Klinikum Lud-
., Germany.metalloproteinase (MMP)-8 and myeloperoxidase (MPO) in pa-
tients with acute ischemic stroke compared to stroke-free controls
[4]. MMP-8 or collagenase-2 is a catalytically competent endopro-
tease that can decisively process extracellular matrix components
and non-matrix bioactive substrates causing tissue destruction and
modulation of immunoresponses [5]. By producing hypochlorite
(HOCl), MPO can not only oxidatively activate latent MMP-8 but
also inactivate tissue inhibitor of matrix metalloproteinase (TIMP)-
1 [6]. TIMP-1 is an important endogenous inhibitor of MMP-8
capable of binding to the active site of MMP-8 in an equimolar
ratio to maintain the physiological conditions. Although some
studies of serum MMP-8, MPO, and TIMP-1 in stroke patients exist,
such observations are limited. In a population-based cohort,
circulating MPO and TIMP-1 concentrations, but not MMP-8, were
associatedwith incident stroke in a 13-year follow-up [7]. However,
little is known on the association between these serum factors and
F. Palm et al. / Atherosclerosis 271 (2018) 9e1410stroke severity and stroke etiology [8]. Based on data from a pre-
liminary case-control study, we tested the hypotheses that serum
levels of MMP-8 along with its activator MPO and TIMP-1 inhibitor
are elevated in patients with ischemic stroke (IS), and especially
that they are associated with stroke severity.
2. Patients and methods
“GENESIS” is a cross-sectional case-control study comprising
470 first-ever ischemic stroke (FEIS) cases (40% women, mean age
66.5± 10.8 years; 60% men, age 65.5± 10.7 years) and 809 age- and
sex-matched controls (41.8% women, 66.4± 11.1; 58.2% men, age
67.9± 9.5 years), randomly selected from the general population.
This study was established within the framework of the Ludwig-
shafen Stroke Study (LuSST), a population-based stroke registry
that started on January 1st, 2006. Detailed descriptions of the LuSSt
registry and the “GENESIS” study have been published recently
[9,10]. The studies were approved by the ethics committee of the
Landes€arztekammer Rheinland-Pfalz (837.333.05(4991)).
2.1. Inclusion and exclusion criteria
Inclusion criteria of both cases and controls covered males and
females between 20 and 80 years of age, permanent residency in
the study area of the LuSSt registry, Caucasian ethnicity and written
informed consent to study participation. Additional inclusion cri-
terion for cases was the diagnosis of a FEIS based on an acute
neurological deficit lasting >24 h with no other cause than cerebral
ischemia. All cases received a cerebral CT or MRI.
Exclusion criteria for cases were acute transient ischemic attack,
intracerebral, subdural or subarachnoid hemorrhage and ischemic
stroke due to cerebral trauma or brain malignancy. Exclusion
criteria for both cases and controls included any previous stroke,
myocardial infarction within past 90 days, dementia, severe apha-
sia, insufficient understanding of the German language or any other
relevant communication barrier and severe disability that pre-
cluded interview participation.
2.2. Recruitment
For recruitment of controls, a random sample of Ludwigshafen
residents was drawn from the population registry including name,
age, sex and address. Subsamples were consecutively taken to
match the age and sex distribution of cases. Those selected received
invitation letters with detailed information on the study and
request for their participation. The participation rate for controls
was 46.6%. The cases included incident stroke cases from the LuSSt
registry. According to the study protocol only in-patients at the
Klinikum Ludwigshafen were asked for participation in “GENESIS”.
This group represents about 89% of all cases in LuSSt. The partici-
pation rate for cases was 73.7%.
2.3. Data collection and laboratory tests
Cases and controls were interviewed by trained personnel using
a standardized questionnaire. We collected data on age, sex,
anthropometric measures, previous diseases, frequency of previous
dentist visits as markers of health behavior, number of teeth,
smoking habits, alcohol intake, physical activity, dietary patterns,
andmedication and social history. In both, cases and controls, blood
pressure was measured after 5min of resting, a 12-lead electro-
cardiogram and a Duplex-sonography of brain supplying arteries
were performed. Venous blood samples were collected in cases and
controls, immediately frozen and stored at 70 C until processing.
In all patients, venipuncture was performed within first 24 h afterhospital admission. Serum inflammation marker concentrations
were determined by commercial ELISA kits according to the man-
ufacturer's instructions. The precision of the analysis are expressed
as coefficient of variation (CV) in percent. Precision for TIMP-1
(Amersham Biotrak, GE Healthcare, Buckinghamshire, UK) was
3.1%, for MPO (Immundiagnostik AG, Bensheim, Germany) 4.8%.
The serum MMP-8 concentrations were determined by a time-
resolved immunofluorometric assay (IFMA) as described previ-
ously, and the interassay coefficient of variation (CV)%was 7.3% [11].
For the calculation of MMP-8 ⁄ TIMP-1 molar ratios, the concen-
trations were converted to molarity using MWs of 65 kDa and
28 kDa as described previously [12]. Leucocyte count (XE
analyserXE-2100; Sysmex) was determined shortly after admission.
2.4. Definition of variables
Cardiovascular risk factors were defined according to current
national and international guidelines and have been described in
detail [13]. Etiological subtypes of IS were ascertained using
modified TOAST criteria (Trial of ORG 10172 in Acute Stroke Treat-
ment) as described recently [13]. Stroke severity was measured by
the National Institutes of Health Stroke Scale (NIHSS) on admission,
as well as by the modified Ranking Scale (mRS) [14,15].
2.5. Statistical analysis
The Chi-squared (X2) test was used to compare categorical data.
The t-test was applied to analyse normally distributed continuous
variables. The Box-Cox method was used to check the compliance
of each laboratory parameter with the normal distribution, taking
into account the group influence (case-control). This method as-
sesses the optimal transformation for the parameters to achieve
normal distribution. If necessary, parameters were log transformed
prior to multivariate analysis. All biomarkers of inflammation were
additionally adjusted for cardiovascular risk-factors and parame-
ters significantly different between cases and controls by univariate
analysis using conditional multiple logistic regression analysis,
stratified for the matching parameters sex and age. In the multi-
variate logistic model it was impossible to include the quotient
MMP-8/TIMP-1 molar ratio. This quotient is a direct derivative of
two predictors already included in the model, and would result in
collinearity. We displayed the univariate statistics just for purpose
of comparability with literature. Logistic regression analysis was
used to calculate odds ratios (OR) for stroke with 95% confidence
intervals (CI). To assess influence of iv-treatment with t-PA, we
additionally performed sensitivity analysis excluding t-PA treated
cases. Investigation of the influence of stroke etiology and NIHSS on
admission on biomarkers of inflammation was performed by
analysis of variance (ANOVA) complemented by Dunn's procedure
for multiple comparisons, which corrects for potential bias by
multiple testing. NIHSS was separated into 4 classes: 0e2; 3e4;
5e9; >9. Influence of stroke etiology and severity was investigated
in restriction to stroke cases. All tests were two-sided and level of
significance was set to 5%. Data were analyzed using the software
package SAS 9.4, and SAS JMP 1.2.
3. Results
Distribution of baseline characteristics is shown in Table 1, as
previously published [10]. Patients were significantly more often
diagnosed as having hypertension, diabetes mellitus, hyperlipid-
emia, coronary artery disease (CAD), myocardial infarct, chronic
heart failure, peripheral artery disease (PAD), and atrial fibrillation
(AF). They were more often physically inactive and more frequently
current smokers. Compared to the control group, the number of
Table 1
Baseline characteristics of cases and controls.
Variable Cases (n¼ 470) Controls (n¼ 809) p-value
Age mean (SD) 65.9 (10.7) 67.3 (10.2) 0.03
Female sex n (%) 188 (40.0%) 338 (41.8%) 0.5
Hypertension n (%) 407 (86.6%) 536 (66.3%) <0.001
Diabetes n (%) 145 (30.9%) 138 (17.1%) <0.001
Hypercholesterolemia n (%) 342 (72.8%) 525 (64.9%) 0.004
Atrial fibrillation n (%) 92 (19.6%) 75 (9.3%) <0.001
History of myocardial infarction n (%) 66 (14.9%) 14 (1.7%) <0.001
Coronary artery disease n (%) 99 (21.1%) 89 (11.0%) <0.001
Congestive heart failure n (%) 60 (12.8%) 48 (5.9%) <0.001
Peripheral artery disease n (%) 46 (9.8%) 17 (2.1%) <0.001
Physical activity n (%)b 150 (31.9%) 447 (55.3%) <0.001
Current smoking n (%) 145 (30.9%) 118 (14.6%) <0.001
High alcohol consumption n (%)c 32 (6.8%) 47 (5.8%) 0.48
Number of teeth (SD) 12.5 (11.0) 15.5 (11.1) <0.001a
Leucocyte count (1000/mm3) mean (SD) 8.3 (2.1) 6.7 (1.8) <0.001
p-value refers to X2-test.
If a is shown, the t-test has been used; b leisure time physical activity that causes sweating 1/week; c > 50 g alcohol intake/day.
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significantly higher in cases. Table 2 presents mean serum MMP-8,
MPO and TIMP-1 concentrations as well as MMP-8/TIMP-1 molar
ratio in patients and controls. All parameters showed significant
differences in univariate and multivariate analysis. They all were
significantly higher in the case group as compared to controls.
Sensitivity analysis leaving out 48 cases that had received iv t-PA
treatment did not notably change the results (Table 3).
The serum levels of inflammatory markers are summarized by
NIHSS on admission in Fig. 1A. Analysis of variance showed sig-
nificant associations between stroke severity and serum levels of
MMP-8 (p < 0.001), MPO (p < 0.001) and MMP-8/TIMP-1 molar
ratio (p < 0.001) but not TIMP-1 (p¼ 0.5) with higher values being
measured in patients with more severe stroke.
Levels of inflammatory markers on admission are shown by
stroke etiology in Fig. 1B. Analysis of variance showed significant
differences between stroke subgroups for MMP-8 (p¼ 0.019) and
MMP8/TIMP-1 ratio (p¼ 0.047), but not for MPO (p¼ 0.113) and
TIMP-1 (p¼ 0.071). In patients with stroke due to small vessel
disease (SVD), MMP-8 serum levels were significantly lower
compared to patients with stroke due to large-vessel disease (LVD)
or cardioembolism (CE). When analysing stroke etiology and
categorized stroke severity in the ANOVA model simultaneously,
only stroke severity remained significant (p¼ 0.009) while stroke
etiology turned non-significant (p¼ 0.241).Table 2
MMP-8, TIMP-1, MPO and MMP-8/TIMP-1-molar ratio in cases and controls.
Variable Univariateb
Cases Controls OR (95%
MMP-8 [ng/ml] meana(95% CI) 58.3 (53.2e63.8)
N¼ 466
24.2 (22.7e25.8)
N¼ 803
8.2 (6.0e
TIMP-1 [ng/ml] meana (95% CI) 127 (123e132)
N¼ 465
122 (119e124)
N¼ 803
3.5 (1.6e
MMP-8/TIMP-1 meana(95% CI) 0.19 (0.17e0.21)
N¼ 465
0.08 (0.08e0.09)
N¼ 803
4.5 (3.4e
MPO [ng/ml] meana (95% CI) 214 (201e227)
N¼ 466
130 (124e137]
N¼ 802
10,1 (6.6
a Means and confidence limits have been calculated under log-transformation, and h
dependent variable, as each unit on the log10-scale means a factor of 10 on metric scale
b Results stratified for age and sex.
c Results stratified for age and sex and adjusted for diabetes, hyperlipidemia, atrial fibr
artery disease, smoking, physical activity, number of teeth and leucocyte count.
d NA (not available): this parameter would cause collinearity and cannot be calculated4. Discussion
In this large, carefully designed case-control study of ischemic
stroke, we found that serum MMP-8, MPO, and TIMP-1 concen-
trations were strongly associated with acute ischemic stroke. While
MMP-8, MPO, and MMP-8/TIMP-1 molar ratio were positively
associated with stroke severity, serum levels of MMP-8 differed
significantly between stroke subtypes.
MMPs play an important role in the cascade leading to brain
injury after an ischemic stroke. MMP-1, -2, -3, -8, -9, -10, -13, and
TIMP-1 are overexpressed in the infarcted brain tissue of stroke
patients compared to non-ischemic areas [16]. Their sources are
activated or infiltrating inflammatory cells such as microglia,
macrophages, and neutrophils, and they contribute to the neuro-
vascular perturbations comprising blood-brain barrier leakage and
inflammatory reactions. Therefore, MMPs have been suggested as
therapeutic targets for stroke. However, since MMPs are needed in
the angiogenesis during the recovery, therapeutic inhibition of
their activity needs to be carefully timed. The most studied MMP in
CVD is MMP-9, but considering the potential of MMPs in treat-
ments, the research should be broadened to other MMP family
members.
MMP-8 is seldom studied specifically in stroke patients [4,17]. In
our study, MMP-8 was directly associated with more severe stroke
as measured by NIHSS. We did not analyze infarct volume, but
stroke severity measured by NIHSS is closely related to it [18]. TheMultivariate per sero-
parameterc
Multivariate all 3 sero-
parametersc
CI) p-value OR (95% CI) p-value OR (95% CI) p-value
11.3) <0.0001 4.9 (3.4e7.2) <.0001 3.4 (2.1e5.3) <0.0001
8.0) 0.025 2.0 (0.7e5.5) 0.186 7.5 (2.5e22.6) <0.0001
5.9) <0.0001 3,0 (2.2e4.1) <.0001 NAd
e15.4) <0.0001 6.6 (4.0e11.0) <.0001 3.7 (2.0e6.9) <0.0001
ave been back-transformed to original scale; OR was calculated per decade of the
.
illation, myocardial infarct, coronary artery disease, chronic heart failure, peripheral
.
Table 3
Sensitivity analysis of MMP-8, TIMP-1, MPO and MMP-8/TIMP-1-molar ratio in cases and controls excluding rt-PA treated cases.
Variable Univariateb Multivariate per sero-
parameterc
Multivariate all 3 sero-
parametersc
Patients Controls OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
MMP-8 [ng/ml] meana (95% CI) 56.5 (51.4e62.1)
N¼ 426
24.2 (22.7e25.8)
N¼ 803
7.7 (5.6e10.6) <0.0001 4.4 (3.0e6.5) <.0001 3.9 (1.9e4.9) <0.0001
TIMP-1 [ng/ml] meana(95% CI) 128 (123e133)
N¼ 425
122 (119e124)
N¼ 803
4.1 (1,7e9.7) 0.001 2.4 (0.8e6.9) 0.11 9.0 (2.9e28.5) <0.0001
MMP-8/TIMP-1 meana(95% CI) 0.18 (0.16e0.20)
N¼ 425
0.08 (0.08e0.09)
N¼ 803
4.2 3.1e5.5) <0.0001 2.7 (1.9e3.8) <.0001 NAd
MPO [ng/ml] meana (95% CI) 210 (197e224)
N¼ 426
130 (124e137]
N¼ 802
9.1 (5.9e14.0) <0.0001 6.0 (3.6e10.0) <.0001 3.8 (2.0e7.0) <0.0001
a Means and confidence limits have been calculated under log-transformation, and have been back-transformed to original scale; OR was calculated per decade of the
dependent variable, as each unit on the log10-scale means a factor of 10 on metric scale.
b Results stratified for age and sex.
c Results stratified for age and sex and adjusted for diabetes, hyperlipidemia, atrial fibrillation, myocardial infarct, coronary artery disease, chronic heart failure, peripheral
artery disease, smoking physical activity, number of teeth and leucocyte count.
d NA (not available): this parameter would cause collinearity and cannot be calculated.
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vascular events is obvious [7,11,12,19e21]. Although we could
demonstrate significant differences between stroke subtypes with
higher serum values of MMP-8 in stroke due to CE or LVD, these
differences are largely explained by CE and LVD contributing to
higher stroke severity [22]. However, further research might focus
on MMP-8 predicting stroke volume. Using longitudinal study-
design, impact of MMP-8 predicting ischemic stroke in certain
stroke etiologies (e.g. asymptomatic carotid stenosis) as well as the
impact on stroke prognosis might be evaluated. This might facili-
tate decision-making process with regards to therapy adjudication
(e.g. carotid endarterectomy), as usage in certain clinical situation is
questionable. In addition, utilizing of MMP-8 determination in
clinical practice might also potentially help to identify stroke
mimics in future, avoiding application of risky therapies such as iv-
treatment with t-PA.
Circulating TIMP-1 concentrations have been consistently
associated with CVD development and prognosis including stroke
[7,23,24] and its associations especially with fatal events have been
repeatedly shown [7,25e27]. In our recent study including several
biomarkers, TIMP-1 concentrations were directly associated with
the highest hazards for stroke and death, and including the
biomarker to the established risk profile improved the risk dis-
criminations [7]. In addition of being an inhibitor of several MMPs,
TIMP-1 plays an important regulatory role in numerous biological
pathways, such as proliferation, apoptosis, and angiogenesis [28]. In
the present study TIMP-1 did not independently associate with
stroke after adjusting for confounders. However, when all
measured biomarkers were entered simultaneously into the final
model, TIMP was independently associated with stroke and its OR
was the highest (9.5/10 units, p < 0.001), describing the importance
of the whole proteolytic and oxidative tissue destructive cascade.
In the present study, MPO had a strong association with both
stroke and its severity, which is in agreement with earlier studies
[4,8]. It has also been reported to predict poor outcome in patients
with significant stenosis [29,30] and in CVD-free populations [7,31].
It is a well-known inflammatory marker produced mainly by
neutrophils as a response to microbial insult. In addition, MPO
enhances the proteolytic activity of MMP-8 and inactivates TIMP-1
and has, therefore, synergetic effect for MMP-8 function [32].
The sources of elevated serum MMP-8 and MPO in CVD has
remained partially unclear. MMP-8 and MPO are stored in different
neutrophil granules and released by degranulation in response to
inflammatory stimuli [33]. Recent studies demonstrated that t-PA
treatment in ischemic stroke patients led to neutrophildegranulationwith consecutive peaks of MMP-8 andMPO followed
by increased production of TIMP-1 [34]. As indicated by sensitivity
analyses, tPA treatment did not significantly contribute to higher
biomarker concentrations in our study. Overall, the serum con-
centrations of these biomarkers are higher than those of plasma
probably due to the sample preparation, where the anticoagulants
inhibit the clotting cascade and complement activation [35].
Therefore, the deviation of serumMMP-8 and MPO concentrations,
but not plasma, are partially explained by the genetic variation of
the complement factor H [36,37]. However, these SNPs did not
significantly associate with the risk of prevalent or incident stroke
in a large cohort with a relatively low number of cases [37]. Further
research is needed to investigate the usefulness of serum or plasma
biomarkers in stroke and the genetic variation of the complement
cascade predisposing to stroke. Our study has several limitations.
Lower response rate in controls might potentially bias study results.
We did not assess infarct volume in stroke patients and there are no
data available on C-reactive protein or renal function in controls.
Longitudinal study design might have given more information on
the course of MMP-8, TIMP-1 and MPO in ischemic stroke.
Strengths of our study include the ample information on stroke risk
factors, stroke etiology and stroke severity.4.1. Conclusion
Our data demonstrate significantly higher serum concentrations
of inflammatory biomarkers MMP-8, MPO and TIMP-1 in acute
ischemic stroke cases compared to controls, even after adjustment
for signs of inflammation (leucocyte count). Serum levels of MMP-8
and MPO were strongly associated with stroke severity and stroke
etiology.Conflict of interest
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Fig. 1. Distribution of biomarkers by stroke severity and stroke etiology.
(A) Distribution of biomarkers by NIHSS on admission (means and 95% CIs). In this graph, MMP-8/TIMP-1 molar ratio has been multiplied by a factor 1000 for scaling reasons. (B)
Distribution of biomarkers by TOAST classification (means and 95% CIs). In this graph, MMP-8/TIMP-1 molar ratio has been multiplied by a factor 1000 for scaling reasons.
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